about
Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasisFundamental effects of PD-1 antibody on the body: a brief report.Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma.Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment.Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review.Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.
P2860
Q28069422-1485F0D6-FDC9-4A29-8AA8-B226E343E2CEQ37082763-AF03C0E9-21C6-48E2-A31F-0A0780198C5AQ40464089-E03E5F98-9E5B-424C-98E2-DC6A8B7863FAQ42355566-5C702BA7-F628-4B10-9B49-6647CED0205EQ49242612-0766E6BF-162F-41F4-ABF2-76F6492A4457Q54982413-F22EE267-2F5D-4F60-9A74-6300E4E26267Q55281964-04654472-F0C2-44BB-B548-881C465DB5FF
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Nivolumab for treating non-small cell lung cancer.
@en
type
label
Nivolumab for treating non-small cell lung cancer.
@en
prefLabel
Nivolumab for treating non-small cell lung cancer.
@en
P2860
P1476
Nivolumab for treating non-small cell lung cancer
@en
P2093
Nicolas Guibert
P2860
P304
P356
10.1517/14712598.2015.1114097
P407
P577
2015-11-16T00:00:00Z